Morgan Stanley Maintains Equal-Weight on Abbott Laboratories, Raises Price Target to $117
Portfolio Pulse from Benzinga Newsdesk
Morgan Stanley has maintained its Equal-Weight rating on Abbott Laboratories while raising the price target from $107 to $117.
October 17, 2024 | 11:27 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Morgan Stanley has maintained its Equal-Weight rating on Abbott Laboratories and increased the price target from $107 to $117, indicating a positive outlook.
The increase in price target from $107 to $117 by Morgan Stanley suggests a positive outlook for Abbott Laboratories, which could lead to a short-term increase in stock price. The maintained Equal-Weight rating indicates a balanced view, but the raised target reflects optimism.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100